The approval of subcutaneous amivantamab allows physicians flexibility in offering treatment for non–small cell lung cancer.

Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...

This article was reviewed by Lynn Marie Morski, MD, JD. Key Takeaways: You can take Mounjaro at any time of day. The best ...

Millions of Australians are set to benefit from the price of medicine going down for the first time in over 20 years. From ...

Therefore, the ideal candidates for a spinal injection are those with symptoms (sciatica) that are predominantly driven by ...

Hemophilia A and B involve deficiencies in coagulation factors VIII and IX, with traditional treatments requiring frequent infusions. Nonfactor therapies, including Hemlibra and rebalancing agents, ...

The top 10 PharmTech videos of the year cover advanced therapies, high-concentration biologics, major mergers and ...

Updated versions of best-selling drugs may mitigate some of the impact of patent cliff losses, but strategy is key in a ...

Lifordi Immunotherapeutics and other biotechnology companies are using antibodies to precisely target drugs in the body.

Delcath Systems, Inc. , ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results ...